Atezolizumab is an engineered humanized monoclonal anti-PD-L1 antibody that inhibits the binding of PD-L1 to PD-1 and B7.1 (also known as CD80), thereby restoring anti-cancer immunity (46). The gene discussed is PDCD1; the disease is cancer.